Ready to revolutionise Type 1 diabetes care?

This is your chance to enhance early detection and care coordination for Type 1 diabetes by integrating innovative, real-world solutions into national health systems. The challenge invites start-ups, SMEs, and consortia to collaborate with Sanofi, Université Paris Cité, and EIT Health in shaping a future where Type 1 diabetes can be identified and managed more effectively—before clinical symptoms appear.

This Open Innovation Challenge is designed to support digital health innovators in developing scalable and personalised solutions. From early detection tools to care pathway enhancements, selected teams will play a key role in transforming how we approach preclinical T1D.

Take part in a tailored acceleration journey, receive expert mentoring, test and integrate your solutions into a national digital platform, and connect with key healthcare stakeholders across Europe. Together, we’ll redefine what’s possible in Type 1 diabetes care.

Applications for the Type 1 Diabetes Challenge are now open. Don’t miss your chance, apply by 24 June. – APPLY NOW 

The Challenge – Screening and care of pre-symptomatic autoimmune Type 1 diabetes

A complete digital platform dedicated to the screening and care of presymptomatic autoimmune Type 1 diabetes

EIT Health, in partnership with Sanofi and Université Paris Cité, is launching a new challenge to accelerate innovation in Type 1 diabetes (T1D) care. The goal is to empower individuals to take charge of their health while advancing research and clinical care through a digital platform composed of a dashboard and a registry of patients—from pre-screening to the clinical stages of T1D.

We are looking for innovative solutions that address at least one of the following areas:

Topic A) Expanding access to T1D pre-screening and streamlining the patient journey

This challenge invites solutions that will form the core of a digital platform, enabling seamless care navigation and longitudinal monitoring for individuals at risk of T1D. Solutions may include:

• Digital health tools that enhance multidisciplinary collaboration through centralised systems and streamlined workflows.
• Improved care coordination through the integration of multimodal data, reducing provider workload and delays in diagnosis.
• Interoperability with existing databases, cohorts, or registries.
• AI-powered early warning systems that analyse clinical histories and symptom patterns for early-stage detection.
• Features such as e-consent, patient referrals, active case management, follow-up calendars, decision trees, appointment booking, and automatic reminders.

Topic B) Supporting long-term patient management and personalised care

We welcome complementary solutions that enrich the patient journey and strengthen support for healthcare professionals. These may include:

• Patient-Reported Outcome Measures (PROMs) for tracking real-time symptom fluctuations and tailoring interventions.
• Secure integration of Electronic Health Records (EHRs) for holistic and real-time patient management.
• Tools that provide insight into behavioural patterns, hospitalisations, and medication adjustments to detect signs of clinical onset.
• Features that help track lifestyle habits—such as diet, stress, and physical activity—enabling more proactive disease management.
• Integration or connectivity with existing T1D apps to improve patient engagement and continuity of care.

By integrating digital tools, AI, and real-world data, this challenge aims to lay the groundwork for a proactive, personalised, and scalable approach to T1D care and research—driving better outcomes from the earliest stages.

Find out all about the challenge

Who should apply

Any solution start-up, SME or consortia that can meet the challenge can apply to the Open Innovation programme.

Applicants must be based in the EU or Horizon Europe-associated countries and present solutions or technologies with a minimum maturity level of IML7 (Validated Solution) according to the CIMIT Healthcare Innovation Cycle.

The specific maturity level must be indicated in the application through self-declaration checkboxes.

To apply as a start-up or SME, it must:

• • Be a for-profit SME in line with the EU definition
  • Be legally incorporated in the EU or Horizon Europe-associated countries
  • Have at least two paid FTEs and a CEO working full-time at the time of applying, covering technical and business backgrounds
  • Have solutions with an innovation maturity level of at least IML7

To apply as a consortia, it must:

• The companies can reply to the challenge as a single entity or in consortium with another/s entities. In that case, all of them should fulfil the requirements stated before.

Upon acceptance of the programme, EIT Health and participating companies must sign a participation agreement.

Applications for the Type 1 Diabetes Challenge are now open. Don’t miss your chance, apply by 24 June. – APPLY NOW